XEOMIN 100 UNIT
INCOBOTULINUMTOXINA : 100 UNIT · DIN 02324032 · MERZ PHARMACEUTICALS GMBH
Health Canada status: MARKETED
What is XEOMIN?
XEOMIN 100 UNIT contains INCOBOTULINUMTOXINA : 100 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02324032, held by MERZ PHARMACEUTICALS GMBH, supplied as POWDER FOR SOLUTION for INTRAMUSCULAR ; INTRAGLANDULAR administration. Health Canada currently lists it as marketed, status dated 23-Sep-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is XEOMIN used for?
Blepharospasm, hemifacial spasm, cervical dystonia (spasmodic torticollis), upper and lower limb spasticity in adults; chronic sialorrhea in adults and pediatric patients (age 2-17, ≥12 kg).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02324032 |
|---|---|
| Brand name | XEOMIN |
| Generic / active ingredient | INCOBOTULINUMTOXINA : 100 UNIT |
| Manufacturer | MERZ PHARMACEUTICALS GMBH |
| Strength | 100 UNIT |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAMUSCULAR ; INTRAGLANDULAR |
| Schedule | Schedule D |
| ATC code | M03AX01 BOTULINUM TOXIN |
| AHFS class | 12:20.20.24 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 23-Sep-2021 |
| Original market date | 2009-07-21 00:00:00 |
How is it administered?
Administered via intramuscular or intraglandular injection by qualified physicians. Dosage is individualized; units are not interchangeable with other botulinum toxin products.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Unopened vials: Store at room temperature (up to 25°C). Reconstituted solution: Store at 2-8°C for up to 24 hours.
How is it supplied?
Vials of type 1 glass with latex-free bromobutyl rubber stopper and aluminum seal. Available in 50, 100, and 200 units.
Contraindications
Hypersensitivity to BoNT/A or ingredients; generalized disorders of muscle activity (e.g., myasthenia gravis, Lambert-Eaton syndrome); infection or inflammation at the injection site.
Warnings and precautions
Distant spread of toxin effect can be life-threatening (breathing/swallowing difficulties). Units are not interchangeable with other botulinum products. Use only by qualified physicians.
What can be used instead?
Other Canadian products sharing ATC code M03AX01 BOTULINUM TOXIN. 12 of 16 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BOTOX | 100 UNIT | POWDER FOR SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 01981501 |
| BOTOX | 200 UNIT | POWDER FOR SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02531585 |
| BOTOX | 50 UNIT | POWDER FOR SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02531577 |
| BOTOX COSMETIC | 100 UNIT | POWDER FOR SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02243721 |
| DYSPORT AESTHETIC | Strength | Powder For Solution | IPSEN BIOPHARMACEUTICALS CANADA INC SUITE 500 5050 Satellite Drive Mississauga Ontario Canada L4W 0G1 | MARKETED | DIN 02387735 |
| DYSPORT THERAPEUTIC | 300 UNIT | POWDER FOR SOLUTION | IPSEN BIOPHARMACEUTICALS CANADA INC | MARKETED | DIN 02460203 |
| DYSPORT THERAPEUTIC | 500 UNIT | POWDER FOR SOLUTION | IPSEN BIOPHARMACEUTICALS CANADA INC | MARKETED | DIN 02456117 |
| LETYBO | 100 UNIT | POWDER FOR SOLUTION | HUGEL CANADA INC. | MARKETED | DIN 02528142 |
| NUCEIVA | 100 UNIT | POWDER FOR SOLUTION | EVOLUS INCORPORATED | MARKETED | DIN 02480158 |
| XEOMIN | 50 UNIT | POWDER FOR SOLUTION | MERZ PHARMACEUTICALS GMBH | MARKETED | DIN 02371081 |
Who else supplies BOTULINUM TOXIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BOTULINUM TOXIN appears in 58 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.